Xeltis Raises $30M to Pioneer Living, Biointegrated Vessels and Valves for the Future of Medicine

Xeltis is thrilled to announce a significant milestone in our journey toward revolutionizing cardiovascular care—we have successfully raised $30 million in our latest funding round. This important investment will propel our mission to develop cutting-edge artificial vessels and valves that are uniquely designed to be gradually replaced by patients’ own living, healthy tissue. At Xeltis, we believe that blending innovative engineering with the body’s natural healing capabilities is the key to creating durable and life-enhancing medical solutions. With this new influx of capital, we are set to accelerate our research and development efforts, expand our clinical trials, and refine our state-of-the-art manufacturing processes. The funding will also enable us to scale our operations and bring our breakthrough products to market faster, ensuring that more patients worldwide have access to therapies that not only address immediate cardiovascular needs but also promote long-term tissue regeneration. Our dedicated team of scientists, engineers, and medical experts is committed to pushing the boundaries of medical technology, and with the support of our investors and partners, we are one step closer to transforming the way heart and vascular diseases are treated. As we embark on this exciting new chapter, we remain steadfast in our mission to provide innovative, life-changing solutions that blend cutting-edge technology with the body’s natural ability to heal. To learn more about our vision, progress, and the latest updates at Xeltis, please visit www.xeltis.com.